Arcuro Medical Exceeds 4,000 Case Milestone
Arcuro Medical has announced a significant milestone, surpassing 4,000 surgical cases worldwide and 1,000 cases in the U.S. with its SuperBall™ Meniscal Repair System. The current version, launched in 2022 with line extensions in 2023, addresses a full range of meniscus tear patterns. CEO Jamal Rushdy expressed excitement about the achievement and future growth prospects.
Dr. Philip Davidson, Arcuro's Medical Director, highlighted the system's unique tensioning mechanism, which provides superior strength and reduced complications compared to other devices. Arcuro has recently made key hires in the U.S., including Jamal Rushdy as CEO and Nick Tonno as Sales Director, to focus on commercial growth. The company plans to provide updates at upcoming industry events in Las Vegas.
Arcuro Medical ha annunciato un traguardo significativo, superando 4.000 casi chirurgici a livello mondiale e 1.000 casi negli Stati Uniti con il suo sistema di riparazione meniscale SuperBall™. L'attuale versione, lanciata nel 2022 con delle estensioni di linea nel 2023, affronta una gamma completa di schemi di strappi meniscali. Il CEO Jamal Rushdy ha espresso entusiasmo per il risultato e le prospettive di crescita futura.
Il Dr. Philip Davidson, Direttore Medico di Arcuro, ha messo in evidenza il meccanismo di tensione unico del sistema, che offre forza superiore e minori complicazioni rispetto ad altri dispositivi. Arcuro ha recentemente effettuato assunzioni chiave negli Stati Uniti, includendo Jamal Rushdy come CEO e Nick Tonno come Direttore Vendite, per concentrarsi sulla crescita commerciale. L'azienda prevede di fornire aggiornamenti in occasione dei prossimi eventi del settore a Las Vegas.
Arcuro Medical ha anunciado un hito significativo, superando 4.000 casos quirúrgicos en todo el mundo y 1.000 casos en EE. UU. con su sistema de reparación meniscal SuperBall™. La versión actual, lanzada en 2022 con extensiones de línea en 2023, aborda un rango completo de patrones de desgarro meniscal. El CEO Jamal Rushdy expresó su emoción por el logro y las perspectivas de crecimiento futuro.
El Dr. Philip Davidson, Director Médico de Arcuro, destacó el mecanismo de tensión único del sistema, que proporciona una mayor resistencia y menos complicaciones en comparación con otros dispositivos. Arcuro ha realizado recientemente contrataciones clave en EE. UU., incluyendo a Jamal Rushdy como CEO y a Nick Tonno como Director de Ventas, para enfocarse en el crecimiento comercial. La empresa planea proporcionar actualizaciones en los próximos eventos de la industria en Las Vegas.
Arcuro Medical이 전 세계 4,000건의 수술 사례와 미국에서 1,000건의 사례를 초과하는 중요한 이정표를 발표했습니다. 현재 버전은 2022년 출시되었으며 2023년에는 라인 확장이 이루어져 무릎 반월판 파열 패턴의 전체 범위를 다룹니다. CEO Jamal Rushdy는 이 성과와 향후 성장 가능성에 대해 흥분을 표했습니다.
Arcuro의 의료 책임자인 Philip Davidson 박사는 이 시스템의 독특한 장력 메커니즘을 강조하며, 다른 장치에 비해 우수한 강도와 감소된 합병증을 제공합니다. Arcuro는 최근 미국에서 Jamal Rushdy를 CEO로, Nick Tonno를 영업 이사로 임명하며 상업적 성장을 집중하기 위해 주요 인재를 영입했습니다. 회사는 라스베이거스에서 열리는 예정된 산업 이벤트에서 업데이트를 제공할 계획입니다.
Arcuro Medical a annoncé une étape importante, dépassant 4 000 cas chirurgicaux dans le monde et 1 000 cas aux États-Unis avec son système de réparation méniscale SuperBall™. La version actuelle, lancée en 2022 avec des extensions de gamme en 2023, aborde une gamme complète de schémas de déchirure du ménisque. Le PDG Jamal Rushdy a exprimé son enthousiasme pour cette réussite et les perspectives de croissance futures.
Le Dr Philip Davidson, Directeur Médical d'Arcuro, a souligné le mécanisme de tension unique du système, qui offre une force supérieure et réduit les complications par rapport à d'autres dispositifs. Arcuro a récemment réalisé des recrutements clés aux États-Unis, notamment Jamal Rushdy en tant que PDG et Nick Tonno en tant que Directeur Commercial, pour se concentrer sur la croissance commerciale. L'entreprise prévoit de fournir des mises à jour lors des prochains événements industriels à Las Vegas.
Arcuro Medical hat einen bedeutenden Meilenstein erreicht und 4.000 chirurgische Fälle weltweit sowie 1.000 Fälle in den USA mit seinem SuperBall™ Meniskus-Reparatursystem überschritten. Die aktuelle Version, die 2022 eingeführt wurde und 2023 Erweiterungen erhielt, deckt ein vollständiges Spektrum von Meniskusrissmustern ab. CEO Jamal Rushdy äußerte seine Begeisterung über diesen Erfolg und die zukünftigen Wachstumsaussichten.
Dr. Philip Davidson, der Medizinische Direktor von Arcuro, hob den einzigartigen Spannungsmechanismus des Systems hervor, der überlegene Stärke und reduzierte Komplikationen im Vergleich zu anderen Geräten bietet. Arcuro hat kürzlich wichtige Einstellungen in den USA vorgenommen, einschließlich Jamal Rushdy als CEO und Nick Tonno als Vertriebsleiter, um den Fokus auf das kommerzielle Wachstum zu legen. Das Unternehmen plant, bei bevorstehenden Branchenevents in Las Vegas Updates bereitzustellen.
- Reached milestone of 4,000 surgical cases worldwide and 1,000 cases in the U.S.
- SuperBall Meniscal Repair System addresses a full range of meniscus tear patterns
- System provides superior strength and reduced deployment failure compared to other devices
- Key hires made to focus on commercial growth in the U.S. market
- None.
Meniscal Repair Innovator Continues
The current version of the SuperBall Meniscal Repair System, commercially launched in 2022, with additional line extensions introduced in late 2023 addresses a full range of meniscus tear patterns.
Jamal Rushdy, Arcuro's CEO, commented, "We are excited to have reached this important milestone of global cases, and most significantly surpassing 1,000 cases here in the
Philip Davidson, MD, Arcuro's Medical Director added, "The SuperBall Meniscal Repair System provides an important all-suture, knotless tool for surgeons to effectively address a wide range of tears. Its unique tensioning mechanism is similar to the inside-out gold standard technique and has been shown to provide superior strength and reduced deployment failure and other complications associated with other meniscus repair devices.[1]"
Recently, Arcuro made two key hires in
Arcuro will provide a company update at the HealthpointCapital Investor Day on September 13, and exhibit at the Orthopaedic Summit: Evolving Techniques (OSET) meeting September 14 to 18, both in
About Arcuro Medical Ltd.
Arcuro Medical Ltd., a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), headquartered in
Contact information:
Jamal Rushdy
Chief Executive Officer
jamal.rushdy@arcuromedical.com
[1] Barber et al. Biomechanical Characteristics of All-Suture Meniscal Repair Devices Compared With PEEK-Anchored Devices and Inside-Out Suture for Meniscal Repair: A Porcine Study. Orthop J Sports Med. 2024;12(5)
View original content:https://www.prnewswire.com/news-releases/arcuro-medical-exceeds-4-000-case-milestone-302214222.html
SOURCE Arcuro Medical
FAQ
How many surgical cases has Arcuro Medical's SuperBall Meniscal Repair System reached globally?
When was the current version of Arcuro Medical's SuperBall Meniscal Repair System launched?
Who are the key new hires at Arcuro Medical for U.S. market growth?
What advantages does the SuperBall Meniscal Repair System offer according to Arcuro's Medical Director?
